Poised for an FDA pitch, Novartis lays out all its PhIII cards on MS drug siponimod
Novartis researchers are laying out all of their Phase III cards for an experimental therapy that aims to become the first approved for cases of secondary progressive multiple sclerosis, a fate that tends to involve everyone diagnosed with the relapsing-remitting form of the disease.
As we were told earlier, investigators tracked a significant 21% reduction in the risk of disease progression among patients taking siponimod (BAF312) after three months, making the primary goal of the study. The full results published Thursday evening in The Lancet provide a more complete portrait. Secondaries in the study demonstrated the therapy:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
